Follow
Mark Ratain
Mark Ratain
Leon O. Jacobson Professor of Medicine, The University of Chicago
Verified email at uchicago.edu
Title
Cited by
Cited by
Year
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer
EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ...
New England Journal of Medicine 363 (18), 1693-1703, 2010
53612010
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma
MJ Ratain, TIM Eisen, WM Stadler, KT Flaherty, SB Kaye, GL Rosner, ...
Journal of Clinical Oncology 24 (16), 2505-2512, 2006
13062006
Tumour heterogeneity in the clinic
PL Bedard, AR Hansen, MJ Ratain, LL Siu
Nature 501 (7467), 355-364, 2013
12932013
Genetic Variants in the UDP-glucuronosyltransferase 1A1 Gene Predict the Risk of Severe Neutropenia of Irinotecan
F Innocenti, SD Undevia, L Iyer, P Xian Chen, S Das, M Kocherginsky, ...
Journal of Clinical Oncology 22 (8), 1382-1388, 2004
11602004
UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity
L Iyer, S Das, L Janisch, M Wen, J Ramirez, T Karrison, GF Fleming, ...
The pharmacogenomics journal 2 (1), 43-47, 2002
8412002
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite …
L Iyer, CD King, PF Whitington, MD Green, SK Roy, TR Tephly, ...
The Journal of clinical investigation 101 (4), 847-854, 1998
8391998
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
T Eisen, T Ahmad, KT Flaherty, M Gore, S Kaye, R Marais, I Gibbens, ...
British journal of cancer 95 (5), 581-586, 2006
7942006
Perceptions of cancer patients and their physicians involved in phase I trials.
C Daugherty, MJ Ratain, E Grochowski, C Stocking, E Kodish, R Mick, ...
Journal of Clinical Oncology 13 (5), 1062-1072, 1995
6311995
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea
E Gupta, TM Lestingi, R Mick, J Ramirez, EE Vokes, MJ Ratain
Cancer research 54 (14), 3723-3725, 1994
6241994
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ...
Journal of Clinical Oncology 29 (19), 2660, 2011
6142011
Measuring financial toxicity as a clinically relevant patient‐reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST)
JA De Souza, BJ Yap, K Wroblewski, V Blinder, FS Araújo, FJ Hlubocky, ...
Cancer 123 (3), 476-484, 2017
6122017
Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors
JJ Luke, JM Lemons, TG Karrison, SP Pitroda, JM Melotek, Y Zha, ...
Journal of Clinical Oncology 36 (16), 1611, 2018
5112018
The development of a financial toxicity patient‐reported outcome in cancer: the COST measure
JA De Souza, BJ Yap, FJ Hlubocky, K Wroblewski, MJ Ratain, D Cella, ...
Cancer 120 (20), 3245-3253, 2014
4842014
Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism
L Iyer, D Hall, S Das, MA Mortell, J Ramírez, S Kim, A Di Rienzo, ...
Clinical Pharmacology & Therapeutics 65 (5), 576-582, 1999
4401999
Oral chemotherapy: rationale and future directions.
MD DeMario, MJ Ratain
Journal of clinical oncology 16 (7), 2557-2567, 1998
3621998
Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung
MJ Ratain, LS Kaminer, JD Bitran, RA Larson, MM Le Beau, C Skosey, ...
3181987
Pharmacogenomics: challenges and opportunities
DM Roden, RB Altman, NL Benowitz, DA Flockhart, KM Giacomini, ...
Annals of internal medicine 145 (10), 749-757, 2006
3052006
The pharmacogenetics research network: from SNP discovery to clinical drug response
KM Giacomini, CM Brett, RB Altman, NL Benowitz, ME Dolan, ...
Clinical Pharmacology & Therapeutics 81 (3), 328-345, 2007
3032007
Pharmacokinetic variability of anticancer agents
SD Undevia, G Gomez-Abuin, MJ Ratain
Nature Reviews Cancer 5 (6), 447-458, 2005
2982005
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents
JE Dancey, KK Dobbin, S Groshen, JM Jessup, AH Hruszkewycz, ...
Clinical cancer research 16 (6), 1745-1755, 2010
2952010
The system can't perform the operation now. Try again later.
Articles 1–20